All News

xray%20spine%20films_0.jpg

IL-17 Inhibitors In Non-Radiographic Axial SpA

d Philip Robinson, MBChB, PhD, FRACP

This meeting sees new data on using anti-IL-17 agents in non-radiographic axial SpA. Up until now these patients have only had TNF inhibitors available, so data about the efficacy of IL17 inhibitors is really important.

Read Article
hospital-834152_640.jpg

Rheumatic Immune-Related Adverse Events: Not Just Another IrAE

d David Liew, FRACP

Rheumatic immune-related adverse events can start at almost any time after the commencement after immune checkpoint inhibitor immunotherapy for cancer, and are liable to persist long after the immunotherapy has ceased, according to data presented at ACR 2019 in Atlanta, Georgia.

Read Article
IPF.lancet.jpg

Systemic JIA-Associated Lung Disease

d Jonathan S. Hausmann, MD

A disease you’ve never heard of is becoming increasingly common and carries a very poor prognosis. 

Read Article
cost.price_.biologic.injectable.jpg

BMS and Celgene Merge as Amgen Buys Otezla

d Jack Cush, MD

Bristol-Myers Squibb (BMS) has completed its $74 billion acquisition of Celgene. With the acquisition complete, Celgene is now a wholly-owned subsidiary of BMS. The combined companies have nine products with more than $1 billion in annual sales.

Read Article
foot%20pain.jpg

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

d Olga Petryna, MD

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades.

Read Article
handcropped.RA_.jpg

Tapering Of Therapy In RA: Maybe Not So Aggressive Next Time

d Philip Robinson, MBChB, PhD, FRACP

This ACR has seen some more great work on tapering of therapy in rheumatoid arthritis. It’s a hot topic and one which I get asked about all the time by my patients.

Read Article
Abstr# 1161: Gadolinium-enhanced MRI of the shoulders showing inflammatory changes in pts with PMR. Helpful to diagnose and detect recurrence. #ACR19 #ACRBest @RheumNow https://t.co/FMvLYtIr3P
Dr. Paul Sufka psufka ( View Tweet)
Abstract L06 shows the efficacy of Emapalumab, an IFN-γ mAb, when given to 9 systemic JIA pts who developed macrophage activation syndrome. Highly effective showing ability to lower steroid use #ACR19 #ACRBest https://t.co/OXTwpkyhlq
Dr. John Cush RheumNow ( View Tweet)
All the NEW Clinical Practice Guidelines for GOUT! 1. Allopurinol is 1st line 2. Start ULT during flare! 3. No tx for asymptomatic hyperuricemia Seems pretty reasonable - surprised no rec for MTX w/ pegloticase #ACR19 @EBRheum Thank you to @philipcrobinson for posting slides! https://t.co/jWFa8KnWqM
Dr. John Cush RheumNow ( View Tweet)
#ACR19 ABST #1590 -3 RCTs show anti-TNFα & IL-12/23 associated w/significant improvement in depressive symptoms in PSA. GO-REVEAL depression ⬇️ 31.2 to 19.5% w/golimumab; PSUMIT1 36.2 to 20.3% & PSUMIT2 37.2 to 21.2% ⬇️ w/UST. minimal change w/PBO in all 3 trials @DrPetryna

Dr. John Cush RheumNow ( View Tweet)

NEW Guidelines for the Management of GCA from #ACR19 in one table 1. Recommend Temp Art. Bx over TA U/S for dx GCA 2. Pts should receive TCZ up front 3. Don't treat asymptomatic CRP, monitor patients closely Overall in line with my practice, though I'm pro TA U/S @EBRheum https://t.co/gP3Ta8wD1E
Dr. John Cush RheumNow ( View Tweet)
#ACR19 ABST #1513 Tofacitinib efficacy in PSA ⬇️ if BL BMI ≥ 35 . Safety consistent across all BL BMI categories. 3 CV events: non-fatal cerebrovascular accident, TIA(both Tofa 5 mg BID, BMI ≥ 30 – < 35), and artery revascularization in PBO; BMI ≥ 35 https://t.co/S1WQDRFqTv https://t.co/oEKTnwUvJP

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR19 abst #2476 Retrospective 2000-18 cohort study on side effects of MTX &TNFi in PSA vs RA: more side effects reported in MTX-PSA (42-46%) compared to MTX-RA pts (26-30%) or PsA or RA pts initiating a TNFi (20-25% of RA and 22-27% of PsA) @DrPetryna https://t.co/Eo3zwDgJMr https://t.co/eaq1gfD1eX

Links:

Dr. John Cush RheumNow ( View Tweet)
60%!!! - Thats the percentage of patients at @NIH's autoinflammatory disease (FEBRILE) cohort that are undifferentiated and do not have a specific disease diagnosis according to Dr. Amanda Ombrello. #ACR19 @hausmannMD

Dr. John Cush RheumNow ( View Tweet)

#ACR19 ABS# 1481 Corrona PsA/SpA Registy: real-world use of COMBINATION Apremilast + biologics happens mostly in pts who received prior biologic therapy & pts not able to achieve MDA. @DrPetryna https://t.co/7OdLBalnPZ

Links:

Dr. John Cush RheumNow ( View Tweet)

The EMA has approved a subcutaneous version of Celltrion infliximab biosimilar, CT-P13 - now called Remsima SC; based on the phase I/III study showing equivalence between SC and IV forms of CT-P13 SC in active rheumatoid arthritis (RA). https://t.co/cJFEk464Wr

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up! Favorite abstracts from ACR 2019. View it here>> https://t.co/LKCC0y4fCr or listen to the podcast >> https://t.co/bsiY1HI9Dn

Links:

Dr. John Cush RheumNow ( View Tweet)

Pre-existing autoimmune disease is NOT a contraindication to checkpoint inhibitor therapy. 29% flare rate, mostly mild and manageable Abstracts#253 #ACR19 @CCalabreseDO

Dr. John Cush RheumNow ( View Tweet)

One of the hardest things about PMR is getting a reliable diagnosis - no biomarker and no histopath. Imaging has potential, and my colleague @drceowen has made a simple algorithm for reliable/replicable PET/CT dx 👍 #ACR19 ABST0755 @drdavidliew https://t.co/XC5iLO2uE9 https://t.co/DHHW2bMMvm

Links:

Dr. John Cush RheumNow ( View Tweet)
VERVE results - Live zoster vaccine safe and effective in >600 patients with autoimmune diseases treated wth TNFi abstr#0824 #ACR19 @CCalabreseDO https://t.co/F8ipuG08O3

Links:

Dr. John Cush RheumNow ( View Tweet)

×